Clinical trial supply is one of those operational disciplines that doesn't get airtime until something breaks. A late kit shipment delays randomization. A mislabeled wallet breaks blinding. A temperature excursion forces a batch retest. The packaging side of trial supply is where most of these problems live, and it's the side sponsors most often outsource.
What clinical trial supply actually covers
A trial supply chain has roughly five layers, each with its own failure modes:
Drug substance. The API itself, manufactured to GMP. Usually the sponsor's responsibility or a separate CMO.
Drug product (primary packaging). Filling the API into vials, blisters, syringes. Sometimes in-house, often outsourced.
Secondary packaging and labeling. Where we live. Wallets, kits, multi-language patient labels, randomization codes, IRT/RTSM integration.
Storage and distribution. GDP-compliant warehousing, validated cold chain lanes, customs handling for international trials.
Drug accountability. Tracking what shipped where, who dispensed what, what came back unused.
Each layer has to talk to the next. A break in handoff between secondary and storage causes problems that don't show up until the trial site reports an unexpected stockout.
The packaging side of trial supply
Three things matter most when you're packaging for a clinical trial:
Low-volume agility
Phase I trials sometimes ship 500 wallets total. Phase II maybe 5,000. Most contract packers can't run profitably at those volumes, so the trial sponsor either pays a premium or compromises on quality. The right partner runs low-volume runs as part of the standard operating model, not as a favor.
Format flexibility between cohorts
A Phase II trial often runs three or four dose cohorts in parallel. Each cohort needs different wallet contents. Format change between cohorts has to take hours, not weeks.
Multi-language booklet labels
International trials need patient labels in seven or nine languages. Booklet labels solve that without exploding the carton inventory. The label has to scan correctly with the IRT system at every site.
Where trials go wrong on the supply side
The pattern we see most often: the trial protocol is locked, the recruitment timeline is set, and the supply chain has six weeks to deliver before site activation. The wallet design hasn't been finalized, the labels haven't been translated, the IRT integration hasn't been tested.
That works if the supply partner is fast and experienced. It breaks badly if the supply partner is figuring out the format on the fly. The right time to involve a supply partner is during protocol design, not after.
Clinical-to-commercial continuity
If the trial reads out positive, the same packaging line should scale to commercial volumes without re-validation. That's a property of the partner, not a guarantee. A partner who runs Phase I batches on a clinical-only line and commercial batches on a separate line is going to put you through a six-month re-validation when you scale up.
We run trial supply and commercial production on the same lines, validated for both. The same wallet that ships 500 units in Phase I ships 500,000 units in commercial launch, with no protocol change.
If you're scoping trial supply
The conversation starts with the protocol: what's the regimen, what's the cohort structure, what languages do you need, what's the cold chain requirement. From that we work backward to the wallet design and the supply chain. Read more about our clinical trial packaging service, or send us the protocol and we'll come back with a packaging concept and a timeline.
Request a free sample now!
